ArticleJournal of cancer prevention2025
Esculetin Attenuates the Migration and Invasion of Human Hepatocellular Carcinoma Cells by Attenuating Matrix Metalloproteinase Activity and Strengthening Tight Junctions.
Article in Journal of cancer prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Esculetin Improves LPS/D-GalN Induced Acute Liver Injury Through AMPK/SIRT1/PGC-1α Signaling Pathway.Antioxidants (Basel, Switzerland) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a highly malignant liver cancer that metastasizes to various organs. Esculetin, a natural dihydroxy coumarin derivative, has been shown to have a variety of pharmacological properties, including immune-enhancing, antioxidant, and anti-inflammatory effects. Esculetin is also known to have potent anticancer activity; however, studies on its ability to inhibit cancer cell metastasis are relatively rare. In this study, we investigated how esculetin inhibits the migration and invasion of human hepatocellular carcinoma cell lines Hep3B and HepG2, and elucidated the underlying mechanisms. Our results showed that esculetin markedly suppressed the migration and invasion of HCC cells, and this was associated with a decrease in the expression and activity of matrix metalloproteinase (MMP)-9 and MMP-2, and increased expression levels of tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2. In addition, esculetin enhanced the tightening of tight junctions by suppressing the expression of claudin family proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.